Continual Reassessment Method: A Likelihood Approach

From MaRDI portal
Revision as of 21:41, 6 February 2024 by Import240129110113 (talk | contribs) (Created automatically from import240129110113)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Publication:4335691

DOI10.2307/2532905zbMath0925.62454OpenAlexW2312270541WikidataQ52304573 ScholiaQ52304573MaRDI QIDQ4335691

John O'Quigley, Larry Zaiqian Shen

Publication date: 12 June 1997

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2532905




Related Items (29)

Continual Reassessment Method for Partial OrderingDesigns for Single- or Multiple-Agent Phase I TrialsPhase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian DesignThe role of minimal sets in dose finding studiesA new design of the continual reassessment methodEscalation with overdose control using ordinal toxicity grades for cancer phase I clinical trialsContinual reassessment and related dose-finding designsThe adaptive accelerated biased coin design for phase I clinical trialsAdaptive clinical trial designs for phase I cancer studiesRetrospective Analysis of Sequential Dose‐Finding DesignsA class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approachesEthical considerations concerning treatment allocation in drug development trialsA Curve‐Free Method for Phase I Clinical TrialsThe Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood ApproachSequential Designs for Phase I Clinical Trials with Late‐Onset ToxicitiesTheoretical study of the continual reassessment methodDesigns for Phase I Clinical Trials with Multiple Courses of Subjects at Different DosesThe Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood ApproachA Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic AgentsAnalysis of ``learn-as-you-go (LAGO) studiesDose-Finding Based on Feasibility and Toxicity in T-cell Infusion TrialsDose-Finding Designs for HIV StudiesCurve-Free and Model-Based Continual Reassessment Method DesignsA Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment MethodContinual Reassessment Method for Ordered GroupsA new sequential approximation methodFlexible link continual reassessment methods for trivariate binary outcome phase I/II trialsOperating characteristics of the standard phase I clinical trial design.Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios






This page was built for publication: Continual Reassessment Method: A Likelihood Approach